arsenic has been researched along with 2-methoxyestradiol in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (90.00) | 29.6817 |
| 2010's | 1 (10.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anderson, KC; Cole, CE; Ryoo, JJ | 1 |
| Anderson, KC; Hayashi, T; Hideshima, T | 1 |
| Carew, JS; Feng, L; Hileman, EO; Huang, P; Keating, MJ; Pelicano, H; Plunkett, W; Zhou, Y | 1 |
| Colomer, D; Montserrat, E; Villamor, N | 1 |
| Bertola, A; Boccadoro, M; Bruno, B; Giaccone, L; Massaia, M; Palumbo, A; Rotta, M | 1 |
| Gao, WR; Hou, J | 1 |
| Chen, QB; Gao, WR; Hou, J; Xiong, H | 1 |
| Anderson, KC; Catley, L; Chauhan, D; Tai, YT | 1 |
| Fu, W; Hou, J; Jiang, H; Wang, D; Yuan, Z; Zhou, L | 1 |
| Chang, HC; Chung, YT; Ho, IL; Hsieh, JT; Huang, KH; Kuo, KL; Lee, PY; Lin, WC; Pu, YS; Shi, CS | 1 |
5 review(s) available for arsenic and 2-methoxyestradiol
| Article | Year |
|---|---|
Novel therapies for multiple myeloma.
Topics: 2-Methoxyestradiol; Angiogenesis Inhibitors; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cysteine Endopeptidases; Enzyme Inhibitors; Estradiol; Humans; Multienzyme Complexes; Multiple Myeloma; Oxides; Proteasome Endopeptidase Complex; Thalidomide; Tissue Extracts | 2002 |
Novel therapies for multiple myeloma.
Topics: 2-Methoxyestradiol; Angiogenesis Inhibitors; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Enzyme Inhibitors; Estradiol; Heterocyclic Compounds, 3-Ring; Humans; Multiple Myeloma; NF-kappa B; Oxides; Phthalazines; Protease Inhibitors; Protein-Tyrosine Kinases; Pyridines; Thalidomide | 2003 |
Cytotoxic effects of B lymphocytes mediated by reactive oxygen species.
Topics: 2-Methoxyestradiol; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; B-Lymphocytes; Benzodiazepines; Cell Death; Estradiol; Hexanones; Humans; Lymphoproliferative Disorders; Oxidative Stress; Oxides; Reactive Oxygen Species; Rituximab; Signal Transduction | 2004 |
New drugs for treatment of multiple myeloma.
Topics: 2-Methoxyestradiol; Angiogenesis Inhibitors; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Diphosphonates; Enzyme Inhibitors; Estradiol; Humans; Multiple Myeloma; Neovascularization, Pathologic; Oxides; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Thalidomide | 2004 |
Perspectives for combination therapy to overcome drug-resistant multiple myeloma.
Topics: 2-Methoxyestradiol; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Drug Resistance, Neoplasm; Enzyme Inhibitors; Estradiol; Histone Deacetylase Inhibitors; Humans; Multiple Myeloma; Oxides; p38 Mitogen-Activated Protein Kinases; Proteasome Inhibitors; Receptor Protein-Tyrosine Kinases; Thalidomide | 2005 |
5 other study(ies) available for arsenic and 2-methoxyestradiol
| Article | Year |
|---|---|
Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism.
Topics: 2-Methoxyestradiol; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cells, Cultured; Estradiol; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mitochondria; Oxides; Oxygen Consumption; Reactive Oxygen Species; Rotenone; Superoxides | 2003 |
[Effect of 2-methoxyestradiol on proliferation and apoptosis of myeloma cell lines].
Topics: 2-Methoxyestradiol; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Proliferation; Dexamethasone; Dose-Response Relationship, Drug; Drug Synergism; Estradiol; Humans; Multiple Myeloma; Oxides; Time Factors; Tumor Cells, Cultured | 2005 |
[Investigation of the effect of 2-methoxyestradiol and arsenic trioxide on the apoptosis-associated gene expression profile of myeloma cells].
Topics: 2-Methoxyestradiol; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Estradiol; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; Oxides; Reverse Transcriptase Polymerase Chain Reaction; Tubulin Modulators | 2005 |
Arsenic trioxide and 2-methoxyestradiol reduce beta-catenin accumulation after proteasome inhibition and enhance the sensitivity of myeloma cells to Bortezomib.
Topics: 2-Methoxyestradiol; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; beta Catenin; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Estradiol; Gene Expression Regulation, Neoplastic; Humans; Multiple Myeloma; Oxides; Proteasome Inhibitors; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Tumor Cells, Cultured | 2008 |
2-methoxyestradiol induces mitotic arrest, apoptosis, and synergistic cytotoxicity with arsenic trioxide in human urothelial carcinoma cells.
Topics: 2-Methoxyestradiol; Aged; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-Associated Death Protein; Caspases; Cell Cycle Checkpoints; Cell Line, Transformed; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Fragmentation; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Activation; Estradiol; Female; Histones; Humans; Mitosis; Oxides; Phosphorylation; Poly(ADP-ribose) Polymerases; Urologic Neoplasms | 2013 |